Role of dopamine receptor agonists in the treatment of early Parkinson's disease

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 4, 2009, Pages

  Bonuccelli, Ubaldo ^a,b   Del Dotto, Paolo ^b   Rascol, Olivier ^c  

^a UNIVERSITY OF PISA   (Italy)

^b Versilia Hospital   (Italy)

^c INSERM   (France)

Author keywords

Dopamine receptor agonists; Neuroprotection; Parkinson's disease

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; ANTIPARKINSON AGENT;

ARTICLE; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DYSKINESIA; EARLY DIAGNOSIS; HALLUCINATION; HUMAN; INCIDENCE; LEG EDEMA; LUNG FIBROSIS; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SOMNOLENCE; VALVULAR HEART DISEASE; VOMITING; ANIMAL; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 72649085309     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70835-1     Document Type: Article

References (75)

1. Calne D.B., Teychenne P.F., Leigh P.N., Bamji A.N., and Greenacre J.K. Treatment of parkinsonism with bromocriptine. Lancet 2 (1974) 1355-1356
2. Ahlskog J.E., and Muenter M.D. Pergolide: long-term use in Parkinson's disease. Mayo Clin Proc 63 (1988) 979-987
3. Goetz C.G., Poewe W., Rascol O., and Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 20 (2005) 523-539
4. Horstink M., Tolosa E., Bonuccelli U., Deuschl G., Friedman A., Kanovsky P., et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 13 (2006) 1170-1185
5. Stowe R.L., Ives N.J., Clarke C., van Hilten J., Ferreira J., Hawker R.J., et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2 (2008) CD006564.
6. Baker W.L., Silver D., White C.M., Kluger J., Aberle J., Patel A.A., et al. Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis. Parkinsonism Relat Disord 15 (2009) 287-294
7. Horowski R. A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view. J Neural Transm 114 (2007) 127-134
8. Bennett Jr. J.P., and Piercey M.F. Pramipexole-a new dopamine agonist for the treatment of Parkinson's disease. J Neurol Sci 163 (1999) 25-31
9. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 65 2 Suppl 1 (2005) S3-S5
10. Guigoni C., Aubert I., Li Q., Gurevich V.V., Benovic J.L., Ferry S., et al. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat Disord 11 Suppl 1 (2005) S25-S29
11. Obeso J.A., Rodríguez-Oroz M.C., Benitez-Temino B., Blesa F.J., Guridi J., Marin C., et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord 23 Suppl 3 (2008) S548-S559
12. Brooks D.J. Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 68 (2000) 685-690
13. Deleu D., Northway M.G., and Hanssens Y. Clinical pharmacokinetic and pharma-codynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 41 (2002) 261-309
14. Metman L.V., Gillepsie M., Farmer C., Bibbiani F., Konitsiotis S., Morris M., et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 24 (2001) 163-169
15. Güldenpfennig W.M., Poole K.H., Sommerville K.W., and Boroojerdi B. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol 28 (2005) 106-110
16. Staal-Schreinemachers A.L., Wesseling H., Kamphuis D.J., vd Burg W., and Lakke J.P. Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study. Neurology 36 (1986) 291-293
17. Riopelle R.J. Bromocriptine and the clinical spectrum of Parkinson's disease. Can J Neurol Sci 14 3 Suppl (1987) 455-459
18. Montastruc J.L., Rascol O., Senard J.M., and Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 57 (1994) 1034-1038
19. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 307 (1993) 469-472
20. Bergamasco B., Benna P., and Scarzella L. Long-term bromocriptine treatment of de novo patients with Parkinson's disease. A seven-year follow-up. Acta Neurol Scand 81 (1990) 383-387
21. Barone P., Bravi D., Bermejo-Pareja F., Marconi R., Kulisevsky J., Malagù S., et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 53 (1999) 573-579
22. Rascol O., Dubois B., Caldas A.C., Senn S., Del Signore S., Lees A., and Parkinson REGAIN Study Group. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. Mov Disord 21 (2006) 2110-2115
23. Adler C.H., Sethi K.D., Hauser R.A., Davis T.L., Hammerstad J.P., Bertoni J., et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 49 (1997) 393-399
24. Brooks D.J., Abbott R.J., Lees A.J., Martignoni E., Philcox D.V., Rascol O., et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 21 (1998) 101-107
25. Stocchi F., Hersh B.P., Scott B.L., Nausieda P.A., Giorgi L., and Ease-PD Monotherapy Study Investigators. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 24 (2008) 2883-2895
26. Hubble J.P., Koller W.C., Cutler N.R., Sramek J.J., Friedman J., Goetz C., et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 18 (1995) 338-347
27. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. JAMA 278 (1997) 125-130
28. Shannon K.M., Bennett Jr. J.P., and Friedman J.H. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 49 (1997) 724-728
29. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 60 (2003) 1721-1728
30. Watts R.L., Jankovic J., Waters C., Rajput A., Boroojerdi B., and Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68 (2007) 272-276
31. Giladi N., Boroojerdi B., Korczyn A.D., Burn D.J., Clarke C.E., Schapira A.H., and SP513 investigators. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22 (2007) 2398-2404
32. Mizuno Y., Kondo T., and Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 45 3 Suppl 3 (1995) S13-S21
33. Korczyn A.D., Brooks D.J., Brunt E.R., Poewe W.H., Rascol O., and Stocchi F. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord 13 (1998) 46-51
34. Korczyn A.D., Brunt E.R., Larsen J.P., Nagy Z., Poewe W.H., and Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 53 (1999) 364-370
35. Rascol A., Guiraud B., Montastruc J.L., David J., and Clanet M. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 42 (1979) 143-150
36. Montastruc J.L., Rascol O., and Senard J.M. Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord 14 (1999) 725-730
37. van Hilten J.J., Ramaker C.C., Stowe R., and Ives N.J. Bromocriptine versus levodopa in early Parkinson's disease. Cochrane Database Syst Rev 4 (2007) CD002258.
38. van Hilten J.J., Ramaker C.C., Stowe R., and Ives N.J. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease. Cochrane Database Syst Rev 4 (2007) CD003634.
39. Katzenschlager R., Head J., Schrag A., Ben-Shlomo Y., Evans A., Lees A.J., and Parkinson's Disease Research Group of the United Kingdom. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71 (2008) 474-480
40. Rinne U.K. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 39 (1989) 336-339
41. Allain H., Destée A., Petit H., Patay M., Schück S., Bentué-Ferrer D., et al. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group. Eur Neurol 44 (2000) 22-30
42. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342 (2000) 1484-1491
43. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284 (2000) 1931-1938
44. Holloway R.G., Shoulson I., Fahn S., Kieburtz K., Lang A., Marek K., et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61 (2004) 1044-1053
45. Rinne U.K., Bracco F., Chouza C., Dupont E., Gershanik O., Marti Masso J.F., et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55 Suppl 1 (1998) 23-30
46. Oertel W.H., Wolters E., Sampaio C., Gimenez-Roldan S., Bergamasco B., Dujardin M., et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 21 (2006) 343-353
47. Hauser R.A., Rascol O., Korczyn A.D., Jon Stoessl A., Watts R.L., Poewe W., et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22 (2007) 2409-2417
48. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 66 (2009) 563-570
49. Bracco F., Battaglia A., Chouza C., Dupont E., Gershanik O., Marti Masso J.F., et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18 (2004) 733-746
50. Schapira A.H. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 72 7 Suppl (2009) S44-S50
51. Olanow C.W., Hauser R.A., Gauger L., Malapira T., Koller W., Hubble J., et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 38 (1995) 771-777
52. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54 (2003) 93-101
53. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
54. Oertel W.H., Schwarz J., Leenders K.L., Sampaio C., Gimenez-Roldan S., Grosset D.G., et al. Results of a 3 year randomized, double-blind, PET-controlled study of Pergolide vs. L-dopa as Monotherapy in Early Parkinson's Disease (PELMOPET-trial). J Neurol Sci 187 Suppl 1 (2001) S444
55. Scheller D., Chan P., Li Q., Wu T., Zhang R., Guan L., et al. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp Neurol 203 (2007) 415-422
56. Müller T., and Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin Neuropharmacol 26 (2003) 109-111
57. Pritchett A.M., Morrison J.F., Edwards W.D., Schaff H.V., Connolly H.M., and Espinosa R.E. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77 (2002) 1280-1286
58. Van Camp G., Flamez A., Cosyns B., Goldstein J., Perdaens C., and Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high dose pergolide. Neurology 61 (2003) 859-861
59. Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., and Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356 (2007) 39-46
60. Schade R., Andersohn F., Suissa S., Haverkamp W., and Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356 (2007) 29-38
61. Junghanns S., Fuhrmann J.T., Simonis G., Oelwein C., Koch R., Strasser R.H., et al. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 22 (2007) 234-238
62. Rothman R.B., Baumann M.H., Savage J.E., Rauser L., McBride A., Hufeisen S.J., et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102 (2000) 2836-2841
63. Horowski R., Jähnichen S., and Pertz H.H. Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role. Mov Disord 19 (2004) 1523-1524
64. Frucht S.J., Greene P.E., and Fahn S. Sleep episodes in Parkinson's disease: a wake-up call. Mov Disord 15 (2000) 601-603
65. Cantor C.R., and Stern M.B. Dopamine agonists and sleep in Parkinson's disease. Neurology 58 4 Suppl 1 (2002) S71-S78
66. Körner Y., Meindorfner C., Möller J.C., Stiasny-Kolster K., Haja D., Cassel W., et al. Predictors of sudden onset of sleep in Parkinson's disease. Mov Disord 19 (2004) 1298-1305
67. Avorn J., Schneeweiss S., Sudarsky L.R., Benner J., Kiyota Y., Levin R., et al. Sudden uncontrollable somnolence and medication use in Parkinson Disease. Arch Neurol 62 (2005) 1242-1248
68. Gjerstad M.D., Alves G., Wentzel-Larsen T., Aarsland D., and Larsen J.P. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?. Neurology 67 (2006) 853-858
69. Dodd M.L., Klos K.J., Bower J.H., Geda Y.E., Josephs K.A., and Ahlskog J.E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62 (2005) 1377-1381
70. Grosset K.A., Macphee G., Pal G., Stewart D., Watt A., Davie J., et al. Problematic gambling on dopamine agonists: Not such a rarity. Mov Disord 21 (2006) 2206-2208
71. Drapier D., Drapier S., Sauleau P., Derkinderen P., Damier P., Allain H., et al. Pathological gambling secondary to dopaminergic therapy in Parkinson's disease. Psychiatry Res 144 (2006) 241-244
72. Avanzi M., Baratti M., Cabrini S., Uber E., Brighetti G., and Bonfà F. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 21 (2006) 2068-2072
73. Voon V., Hassan K., Zurowski M., Duff-Canning S., de Souza M., Fox S., et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 66 (2006) 1750-1752
74. Voon V., Thomsen T., Miyasaki J.M., de Souza M., Shafro A., Fox S.H., et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 64 (2007) 212-216
75. Olanow C.W., Rascol O., Hauser R., Feigin P.D., Jankovic J., Lang A., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361 (2009) 1268-1278